Vontobel Holding Ltd. Acquires New Stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL)

Vontobel Holding Ltd. acquired a new stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 35,000 shares of the company’s stock, valued at approximately $34,000. Vontobel Holding Ltd. owned 0.08% of Werewolf Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. D. E. Shaw & Co. Inc. purchased a new stake in shares of Werewolf Therapeutics in the 4th quarter valued at $26,000. Regal Investment Advisors LLC raised its holdings in shares of Werewolf Therapeutics by 88.1% in the 4th quarter. Regal Investment Advisors LLC now owns 27,204 shares of the company’s stock valued at $40,000 after buying an additional 12,745 shares during the period. Jane Street Group LLC grew its stake in Werewolf Therapeutics by 261.2% during the 4th quarter. Jane Street Group LLC now owns 54,713 shares of the company’s stock worth $81,000 after purchasing an additional 39,564 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Werewolf Therapeutics by 372.4% during the 4th quarter. JPMorgan Chase & Co. now owns 62,928 shares of the company’s stock worth $93,000 after purchasing an additional 49,608 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Werewolf Therapeutics by 23.1% during the 4th quarter. Bank of New York Mellon Corp now owns 71,300 shares of the company’s stock worth $106,000 after purchasing an additional 13,372 shares in the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Trading Up 0.9%

HOWL opened at $1.07 on Thursday. The business has a fifty day moving average price of $1.13 and a 200 day moving average price of $1.18. The stock has a market capitalization of $48.01 million, a price-to-earnings ratio of -0.64 and a beta of 0.62. Werewolf Therapeutics, Inc. has a 12 month low of $0.60 and a 12 month high of $4.18. The company has a debt-to-equity ratio of 0.46, a current ratio of 8.09 and a quick ratio of 8.09.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.04. Sell-side analysts expect that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HOWL has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Werewolf Therapeutics in a research note on Wednesday, March 12th. Wedbush lowered their target price on Werewolf Therapeutics from $8.00 to $6.00 and set an “outperform” rating for the company in a research note on Friday, May 9th.

Insider Activity

In other news, Director Ra Capital Management, L.P. bought 162,539 shares of the firm’s stock in a transaction that occurred on Wednesday, May 14th. The stock was purchased at an average cost of $0.98 per share, with a total value of $159,288.22. Following the transaction, the director directly owned 6,237,482 shares in the company, valued at $6,112,732.36. This trade represents a 2.68% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 23.60% of the stock is currently owned by company insiders.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.